Obligations that arrive in stages
Early research companies often deal mostly with grant terms, laboratory safety, and agreements governing the materials and data they receive. Once human studies begin, attention shifts to clinical research rules, informed consent, and oversight by institutional review boards. A commercial launch brings rules on promotion, pricing, and interactions with prescribers, along with reporting to government health programs. Each step adds obligations without removing the earlier ones, and the people who handled the earlier stage are not always the right people for the next. Companies that partner with a larger firm for commercialization often inherit some of that partner's expectations through the contract. A life sciences compliance program planned only for the current stage tends to fall behind the company it is meant to serve.
Issues that cross every stage
Some questions follow a company from its founding onward. Data from research participants and patients is governed by privacy laws that differ depending on where the data comes from, and HIPAA may or may not apply to it. Collaborations with academic institutions carry conflict-of-interest and publication terms that affect what the company controls. Shipping biological materials or technology across borders can raise export control and customs issues. Federal funding brings its own reporting rules, including rules about inventions developed with that money, and those obligations can surface years later in diligence.
Building the program to fit
A start-up does not need a large pharmaceutical company's compliance manual, and adopting one wholesale usually produces policies nobody follows. We begin with where the company is now, what it plans for the next stage, and what investors, partners, and regulators are already asking about. From there we identify the few policies and controls that matter most now and the ones that can reasonably wait. Diligence in a financing or a partnership often tests these documents, so they should match actual practice. We revisit the program as the company's activities change, rather than treating it as finished.
